Gilead Sciences

Biopharmaceutical company in virology, oncology, and inflammation, applying AI to small-molecule discovery through its Genesis Therapeutics collaboration.

Company type

Large biopharmaceutical company

Headquarters

Foster City, United States

Website

https://www.gilead.com

Profile last verified

2026-07-29

AI Partnerships & Deployments

• 2024-09-10 — Strategic AI small-molecule discovery collaboration with Genesis Therapeutics (Genesis Therapeutics). Collaboration using Genesis' GEMS AI platform to discover and develop novel small-molecule therapies against multiple targets. Gilead paid $35 million upfront in cash and equity, with eligibility for preclinical, clinical, regulatory, and commercial milestone payments plus royalties. Disclosed: $35M upfront (cash and equity) plus milestones and royalties. Source: Gilead Sciences press release (accessed 2026-07-29)